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ABSTRACT
Purpose. For years, 5-ﬂuorouracil (5-FU) has been the
backbone of radiochemotherapy (RCT) of locally advanced
rectal cancer. Its main target, thymidylate synthase (TS), is
speculated to be an important biomarker for response
prediction and long-term prognosis. In this study, we
analyzed TS expression in the rectal cancer tissue of 208
patients to evaluate its predictive/prognostic potential.
Methods. All patients included were diagnosed with
locally advanced adenocarcinoma of the rectum (UICC II
and III) and were treated within randomized clinical trials
of the German Rectal Cancer Study Group. Preoperative
RCT (50.4 Gy and concomitant either 5-FU or 5-FU and
oxaliplatin) was administered in 167 patients followed by
surgical resection with total mesorectal excision (TME).
Another 41 patients received postoperative RCT. TS levels
and further clinicopathological parameters were assessed in
univariate and multivariate analyses. Additionally, a TS
gene polymorphism was analyzed with respect to the
intratumoral protein levels.
Results. Low TS expression in pretreatment biopsies
correlated with impaired patient survival (p = 0.015).
Analysis of a 28-bp repeat revealed a correlation between
the *3/*3 genotype and high TS expression in prethera-
peutic biopsies. In this study, a correlation of TS
expression and grade of RCT-induced tumor regression
was not found. Histopathological examination conﬁrmed a
complete tumor remission in 16 patients (9.6%).
Analyses of the resection specimen indicated an unfavor-
able prognosis for patients with low intratumoral TS
expression in case of detected lymph node metastases
(p = 0.04).
Conclusions. TS can serve as a prognostic biomarker
indicating an unfavorable prognosis for patients with low
TS expression.
During the past two decades, preoperative multimodal
strategies and optimized surgical procedures, including
total mesorectal excision (TME), have been increasingly
used to treat UICC (Union International Contre le Cancer)
stage II and III rectal cancer.
1–3 In particular, several studies
have demonstrated that neoadjuvant 5-ﬂuorouracil (5-FU)-
based radiochemotherapy (RCT) signiﬁcantly improves
locoregional control, as well as sphincter preservation and
the toxicity proﬁle, compared with postoperative RCT.
4–7
Therefore, neoadjuvant RCT is recommended as the stan-
dard treatment for locally advanced rectal cancer.
8
Although RCT-induced complete tumor regression, T-level
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parameters, no reliable biomarkers for individual prognosis
and response prediction to neoadjuvant RCT have yet been
established.
6,9–12
With a 5-year distant relapse rate of 30–40%, the
occurrence of systemic metastatic spread remains the pre-
dominantmodeoffailureandlimitslong-termprognosis.
7,13
From the clinical point of view, the implementation of more
risk-adapted therapy approaches is required. This notion
appliestoboththeneoadjuvantpartofmultimodaltreatment
and the adjuvant situation because evidence on adju-
vant chemotherapy (CT) is controversially discussed.
14,15
Currently, ongoing clinical trials, such as the CAO/ARO/
AIO-04 trial [EudraCT-No: 2006-002385]
16, are testing
intensiﬁed neoadjuvant RCT for improving local complete
response (pCR) and adjuvant CT to increase overall cancer-
speciﬁc survival (CSS). Nevertheless, the approved anti-
metabolite and radiosensitizer 5-FU remains the backbone
of systemic therapy.
17,18
In 5-FU metabolism, thymidylate synthase (TS) is the
central molecular target; TS is essential for de novo DNA
synthesis.
19 A speciﬁc connection between TS expression
and tumor cell viability was previously shown.
20 In several
small-sized studies, the potential of TS as a valid bio-
marker has been investigated in multimodal treatment
regimens; however, no ﬁnal conclusion about its predictive
and/or prognostic value has been gained.
21–23
Previous studies suggest that pretherapeutic TS expres-
sion may predict individual response to neoadjuvant 5-FU-
based RCT in rectal cancer.
24–26 Additionally, the TS level
in residual tumor specimens after RCT may be of prog-
nostic value and allow stratiﬁcation of patients with
different risk proﬁles for recurrence. The purpose of this
study was to evaluate the potential of TS as a predictive
and prognostic biomarker in patients with rectal cancer,
who were treated with standard preoperative 5-FU or 5-FU/
oxaliplatin protocols. TS protein levels were evaluated by
immunohistochemical (IHC) staining of pretherapeutic
biopsies and residual tumors after surgery. A tandem repeat
polymorphism within the TS gene, which has been
repeatedly discussed for the efﬁcacy of 5-FU-based che-
motherapy, was identiﬁed in the germline DNA extracted
from the peripheral blood cells of these patients.
27
PATIENTS AND METHODS
Eligibility and Clinical Assessments
Patients (mean age, 62.6 ± 9.5 years; 145 men and 63
women) with primary rectal cancer received 5-FU-based
RCT within randomized clinical phase-II/-III-trials of the
German Rectal Cancer Study Group (CAO/ARO/AIO-04,
XelOX-trial, CAO/ARO/AIO-94). One hundred sixty-
seven (80.3%) patients received neoadjuvantly 5-FU
(n = 103) or 5-FU and oxaliplatin (n = 64) (Fig. 1).
Forty-one (19.7%) patients were conveyed to primary
surgery, followed by adjuvant 5-FU RCT. All patients were
treated at the Department of General and Visceral Surgery,
University Medical Center Go ¨ttingen (Go ¨ttingen, Ger-
many), between 1998 and 2009. Eligibility criteria
included histologically conﬁrmed adenocarcinoma, located
no more than 16 cm above the anocutaneous verge, as
measured by rigid rectoscopy, a complete medical history,
physical examination, peripheral blood cell count, chest
x-ray, abdominal ultrasound, and carcinoembryonic anti-
gen (CEA) serum levels.
28 Furthermore, staging was
completed by endorectal ultrasound (EUS) and contrast-
enhanced magnetic resonance imaging (MRI) of the pelvis
to conﬁrm locally advanced but resectable rectal cancer.
Contrast-enhanced computed tomographic (CT) scans of
the chest, abdomen, and pelvis were performed to identify
patients with distant metastatic disease. At the time of
staging, all patients had an Eastern Cooperative Oncology
Group (ECOG) performance status of B2.
29 The study was
approved by the medical ethics committee of the Univer-
sity of Go ¨ttingen.
Multimodal Treatment: Radiochemotherapy
and Surgery
Preoperative radiotherapy with a total dose of 50.4 Gy
was delivered in 28 fractions of 1.8 Gy in three-dimen-
sional conformal irradiation by a three-ﬁeld box technique
with 20-MV photons.
30,31 In 103 patients, 5-FU was
scheduled as a 120-h infusion of 1,000 mg/m
2 per day
during weeks 1 and 5. The same RCT regimen was applied
postoperatively to the 41 patients receiving adjuvant RCT
(Fig. 1). In 64 patients who were randomized to an inten-
siﬁed protocol, neoadjuvant RCT was applied as a
combination of 5-FU (250 mg/m
2/d) days 1–14 and 22–35
and oxaliplatin (50 mg/m
2/d) days 1, 8, 22, and 29. Six
weeks after the completion of neoadjuvant RCT, curative
surgery with TME was performed.
9
Four to six weeks after surgery, multimodal therapy was
completed with four cycles of 5-FU (500 mg/m
2/d) bolus
infusion(days1to5)orwitheightcyclesof5-FU(2,400 mg/
m
2) continuous infusion with folinic acid (400 mg/m
2) and
oxaliplatin (100 mg/m
2) bolus infusion (Fig. 1).
Histopathological Staging and Tumor Regression
Grading
Complete pathological staging included ypTNM stage
according to the current TNM classiﬁcation; the evaluation
of longitudinal and circumferential resection margins with
Thymidylate Synthase in Rectal Cancer 2443an aimed tumor distance of B1 mm and intramural or
extramural vascular and perineural invasion and the quality
assessment of TME based on MERCURY criteria.
32–35
Nodal staging included the histological evaluation of all
detected lymph nodes and the determination of lymph node
ratio in all cases.
Histopathological Staging and Classiﬁcation of Tumor
Response
RCT-induced tumor regression was denoted based on a
semiquantitative ﬁve-point tumor regression grading
(TRG) system.
6,36 pCR was deﬁned as the absence of any
viable tumor cells in the primary tumor and all detected
lymph nodes.
37 The standardized clinical setting and
specimen preparation warrants a marginal bias, according
to the REMARK guidelines for biomarker studies.
38
Follow-up
During treatment, all patients were monitored on a
weekly basis. Long-term follow-up included rectoscopy,
abdominal ultrasound, computed tomography of the abdo-
men and pelvis, as well as chest x-ray at regular intervals
according to the study protocols. Disease-free survival
(DFS)was deﬁned as the intervalbetweensurgical resection
and any evidence of local or systemic cancer recur-
rence. Histologic conﬁrmation of cancer recurrence was
encouraged. Alternate acceptable criteria included speciﬁc
imaging ﬁndings with concurrent elevation of CEA serum
levels. CSS was deﬁned as the interval between surgical
resection and cancer-related death. Follow-up examinations
were performed at 3-month intervals within the ﬁrst 2 years
and at 6-month intervals after 2 years.
8
Tissue Samples and Immunohistochemical Evaluation
of TS Expression
Tumor specimens were collected at the time of the ﬁrst
biopsy procedure and at the time of surgery (Fig. 1). The
TS protein level was assessed on parafﬁn-embedded,
matched tissue samples from pretreatment tumor biopsies
and surgical specimens from the same patients. A stan-
dardized immunohistochemical staining technique was
performed using a Ventana BenchMark XT immunostainer
(Ventana, Tucson, AZ) with a mouse anti-human mono-
clonal antibody to TS (anti-human TS [Rabbit] Code:
100-401-199 Rockland, PA) at a dilution of 1:100. Heat
epitope retrieval using the immunostainer was performed
for 60 min at 100C. The anti-TS antibody was incubated
at 37C for 28 min. The enzymatic reactivity was visual-
ized with alkaline phosphatase (Red Detection Kit, Roche
Ventana, Mannheim, Germany).
The immunohistochemical slides were independently
evaluated and interpreted by two different observers in a
blinded manner, without the knowledge of the clinical and
FIG. 1 Study design. EUS
endorectal ultrasound; CT
computed tomography; MRI
magnetic resonance imaging;
CEA carcinoembryonic antigen;
RCT radiochemotherapy; 5-FU
5-ﬂuorouracil; ox oxaliplatin;
TME total mesorectal excision;
APE abdominoperineal
extirpation; CTx chemotherapy;
IHC immunohistochemical
staining
2444 L.-C. Conradi et al.follow-up data. TS immunoreactivity was scored for
staining intensity (Fig. 2) and proportion of positive cells
when at least 50 tumor cells were accessible. The slides
were screened at a low power for pattern and distribution of
staining; a higher magniﬁcation (940) was used to deter-
mine the staining intensity. To record antibody expression,
the scoring method by Remmele and Stegner
39 was adop-
ted and slightly modiﬁed to incorporate heterogeneous
staining intensities and to obtain a more accurate score.
Staining was semiquantitatively evaluated as follows:
staining intensity was scored as none (0), weak (1), mod-
erate (2), and strong (3). The tumor cell percentage of each
of these four intensity classes was documented (as q0, q1,
q2, and q3, respectively). The tumor percentage (s) was
deﬁned as the total percentage of positive tumor cells
(q1 ? q2 ? q3). The tumor cell percentage was catego-
rized into ﬁve groups: 0 = 0%; 1 = (0–25%); 2 =
(25–50%); 3 = (50–75%); 4 = (75–100%), as the tumor
percentage score. The weighted mean of the staining
scores weighted by the observed percentages (1(q1/s) ?
2(q2/s) ? 3(q3/s))/3 was calculated and deﬁned as the
tumor staining intensity score. For further statistical anal-
ysis, the tumor staining intensity score (range 0–3) and the
tumor percentage score (range 0–4) were multiplied to
obtain the ﬁnal TS score (range 0–12). In Kaplan-Meier
analyses, low TS expression was deﬁned as a TS score\7
and high expression as TS scores C7, according to the
observed median. Likewise, the cutoff score applied for
analyses of pretherapeutic biopsies was set to 4, in accor-
dance with the median.
Genotyping of TS 28-bp Tandem Repeats
In the TS gene, the number of the TS 28-bp repeat
polymorphism (abbreviated as 28R, rs34743033 according
to the dbSNP database: http://www.ncbi.nlm.nih.gov/snp)
was genotyped in lymphocytes by fragment length analy-
sis. At ﬁrst, the genomic fragment containing this repeat
was ampliﬁed by conventional PCR using Taq polymerase
with Q-solution (Qiagen, Hilden, Germany) with FAM
labeling of one primer at the 50 end. PCR conditions were
35 cycles, each consisting of a 50-s denaturation at 95C, a
30-s annealing at 68.5C, and a 60-s elongation at 72C.
Primer sequences (each in 5’ to 3’ direction) were
GTGGCTCCTGCGTTTCCCC and FAM-TCCGAGCCG
GCCACAGGCAT, yielding the fragments of 212 bp (in
case of two 28R repeats, denoted as 28R*2), 240 bp (three
28R repeats, 28R*3), and, as found only once, 268 bp (four
28R repeats, 28R*4).
40 The fragments with the FAM-
labeled primer were analyzed on a sequencing machine
(3100 Genetic Analyzer, Applied Biosystems, Foster City,
CA). Genescan 400HD (Applied Biosystems) was used as
the size standard to allocate fragment length. Determined
genotypes were in Hardy-Weinberg equilibrium, as asses-
sed by v
2 test (p = 0.8).
Statistical Analysis
Correlation analysis of the TS score with clinical
outcome variables was assessed using the Spearman
correlation coefﬁcient and was tested for statistical sig-
niﬁcance. The impact of the TS score on DFS and CSS
was statistically tested using Cox proportional-hazards
regression models. For graphical display, the TS score
was categorized as low or high and was expressed as a
Kaplan-Meier plot. The comparative analysis of pati-
ents’ clinicopathological characteristics between different
groups was performed using a v
2 test. To conﬁrm the
prognostic value of further clinicopathologic parameters,
these factors were tested in a multivariate model.
Additionally, the impact on the following variables that
were available at the time of staging (gender, age, uN,
FIG. 2 Examples of TS immunohistochemical staining of human rectal adenocarcinoma cells. a Strong staining intensity in rectal cancer cells.
b Cancer cells with a moderate staining pattern. c Negative tumor cells for TS staining
Thymidylate Synthase in Rectal Cancer 2445TABLE 1 Clinical parameters and histopathologic characteristics of examined patient cohorts
Therapy regimen No neoadjuvant RCT Neoadjuvant RCT with
standard 5-FU
Neoadjuvant RCT with
5-FU/oxaliplatin
p*
Parameter No. of patients
(n = 41)
% No. of patients
(n = 103)
% No. of patients
(n = 64)
%
Age (yr) 0.85
Mean 63.3 62.9 61.8
Range 39–75 35–81 36–81
Gender 0.6
Male 28 68 75 73 42 66
Female 13 32 28 27 22 34
Tumor distance from anal verge (cm) 0.02
0–6 12 29 39 38 31 48
[6–12 25 54 59 57 31 48
[12–16 7 17 5 5 2 3
cT stage 0.06
2 6 1 5 33 23
3 3 3 8 0 9 28 9 5 99 2
42 5 8 8 3 5
cN stage 0.11
Positive 25 61 73 71 51 80
Negative 15 39 30 29 13 20
cUICC stage 0.23
II 14 34 31 30 13 20
III 27 66 72 70 51 80
Surgical procedure
# 0.35
Low anterior resection 31 76 64 62 48 75
Abdominoperineal resection 9 22 37 36 15 23
Hartmann‘s procedure 1 2 2 2 1 2
Postoperative parameters
Resection status (including CRM)
R0 41 100 103 100 64 100
R 1 0 0 00 00
R 2 0 0 00 00
Tumor regression grading 0.33
0 No regression – – 0 0 0 0
1 Minor regression (\25%) – – 14 14 6 9
2 Moderate regression (\50%) – – 26 25 10 16
3 Good regression (\80%) – – 54 52 41 64
4 Total regression (100%) – – 9 9 7 11
(y)pT stage 0.1
00 0 9 9 9 1 4
11 2 8 8 9 1 4
2 9 22 25 24 14 22
3 2 9 7 1 5 55 3 2 84 4
42 5 6 6 4 6
(y)pN stage 0.09
0 2 1 5 2 6 76 5 4 67 2
1 1 0 2 4 2 52 4 1 32 0
21 0 2 4 1 1 1 1 5 8
2446 L.-C. Conradi et al.uT, planned neoadjuvant treatment, and TS score in a
Cox model from the staining of the biopsy) were
assessed both in univariate analyses and a multivariate
model. The TS scores of all patients with lymph node
metastases after resection also were analyzed, including
the following variables: (y)pT, applied neoadjuvant
treatment and pretherapeutically measured TS score from
tumor biopsy in a multivariate model. The global sig-
niﬁcance level was set to a = 5%. All statistical analyses
were performed using the R statistical computing envi-
ronment version 2.11.0.
41
RESULTS
Patient Characteristics and Recurrence
With respect to the primary tumor localization of rectal
adenocarcinoma at staging (Table 1), 82 (39.4%) tumors
TABLE 1 continued
Therapy regimen No neoadjuvant RCT Neoadjuvant RCT with
standard 5-FU
Neoadjuvant RCT with
5-FU/oxaliplatin
p*
Parameter No. of patients
(n = 41)
% No. of patients
(n = 103)
% No. of patients
(n = 64)
%
(y)pUICC stage 0.01
00 0 8 8 9 1 4
I 5 12 24 23 22 34
II 16 39 32 31 13 20
III 19 46 30 29 15 23
I V 1 2 99 58
Follow-up (145 months, last update 01/2010; median follow-up, 57 months)
Cancer recurrence
None 31 68 78 75 49 76
Local 1 5 0 0 1 2
Distant 4 11 23 22 13 20
Local and distant (synchronous) 5 16 3 3 1 2
Distant metastases 9 22 26 25 14 21
Hepar 4 45 8 31 4 29
Pulmo 3 33 10 39 3 21
Hepar and pulmo 1 11 4 15 3 21
Peritoneal and/or osseus 1 11 4 15 4 29
Follow-up time
Mean 88 50 33
Range 2–154 3–141 0–82
Cancer-related death 6 15 15 15 6 10
TS expression in cUICC-II/-III rectal cancer cells
TS biopsy 0.82
Mean 3.85 3.88 4.02
Min - Max 0–8 0–1 0-8
TS tumor 0.04
Mean 6.03 6.90 7.28
Min - Max 1–11 1–12 0–11
TS genotype 0.72
2 2 42 4 1 72 0 1 73 3
2 4 0 0 11 00
3 2 95 3 4 14 9 2 44 6
3 3 42 4 2 42 9 1 12 1
* P values from Chi-square test; for age difference from Kruskal–Wallis rank-sum test
# In all cases TME was performed
Thymidylate Synthase in Rectal Cancer 2447were localized in the lower third (0–6 cm), 115 (55.2%)
tumors were localized in the middle third ([6–12 cm), and
14 (6.7%) tumors were localized in the upper third
([12–16 cm) of the rectum. The surgical procedures con-
sisted of 143 (68.8%) low anterior resections, 61 (29.3%)
abdominoperinealresections,and4discontinuousresections
(Hartmann‘s procedure) (1.4%), all including TME. Focus-
ing on the efﬁcacy of neoadjuvant RCT in this study, the
pretherapeutic cUICC staging and postoperative ypUICC
tumor staging results are summarized in Table 1. By com-
paring pretherapeutic staging results and histopathological
ﬁndings after surgery, T-level downsizing was found in 78
(46.7%)patients,andUICCdownstagingwasachievedin97
(58%) patients. Median follow-up was 57 months. Cancer
recurrence was observed in 41 (23.2%) patients after neo-
adjuvant RCT and in 10 (24.3%) patients who underwent
adjuvant RCT. In patients with cancer recurrence, the pre-
dominant relapse was detected intrahepatic in 24 (47%)
cases of 51 patients with recurrent disease (Table 1).
Pretherapeutic TS expression in Correlation
with Tumor Regression Grading
The current study did not reveal a correlation between
pretreatment TS expression and RCT-induced histopa-
thological tumor regression (TRG). TRG had no prognostic
impact on DFS in this study, unless a complete tumor
remission was achieved (p = 0.46; r =-0.16). Never-
theless, the long-term survival of patients with pCR after
neoadjuvant RCT and extensive histopathological workup
was excellent because no patient with pCR (n = 16; 9.5%)
exhibited cancer recurrence during the follow-up time.
PRETHERAPEUTIC TS EXPRESSION
AND PROGNOSIS
TS expression in pretherapeutic biopsies showed
a signiﬁcant correlation with cancer-related death, dem-
onstrating a beneﬁt for patients with high TS expression
(p = 0.0406; Fig. 3). The multivariate analyses (Table 2)
of pretreatment TS score and other parameters available at
the time of initial staging (age, uN, uT, and neoadjuvant
treatment) revealed a signiﬁcant correlation of low TS
expression with a decrease in CSS (p = 0.01) and con-
ﬁrmed baseline TS expression levels as an independent
prognostic marker.
Prognostic Value of Intratumoral TS Expression
in Resected Specimens
In patients with histologically conﬁrmed lymph node
metastases,intratumoralTSexpressionoftheresectedtumor
specimens showed prognostic relevance. There was a sig-
niﬁcant decrease of DFS (p = 0.015) in patients with lymph
node metastases (n = 74) and low TS expression (Fig. 4).
Included in a multivariate cox regression model
(Table 2), TS expression in nodal-positive patients was
signiﬁcantly associated with a decreased DFS (p = 0.03).
Findings in Patients with ypN0 Status
In nodal-negative patients, TS expression had no inﬂu-
ence on DFS (p = 0.168). Furthermore, no signiﬁcant
differences in local and distant recurrences were observed
within the three groups of patients.
TS Genotype does Correlate with Intratumoral TS
Protein Expression
Genotypes of all patients with available blood samples
(n = 152) for the TS 28-bp tandem repeat polymorphism
revealed the following distribution: 39 patients (25.7%)
with *3/*3; 74 patients (48.7%) with *3/*2; 38 patients
(25%) with *2/*2; and 1 patient with the *2/*4 allele. The
correlation of the TS genotype *3/*3 with TS protein
expression revealed a trend of higher expression levels in
biopsy specimens (p = 0.059) and tumor specimens
(p = 0.229), but the difference was not statistically
signiﬁcant.
This result is consistent with the ﬁndings from previous
analyses that revealed a coherency of several 28-bp repeats
with higher intracellular TS expression.
42 The statistical
analysis of the TS genotype with local response, other
clinicopathological ﬁndings (TRG, T-level downsizing,
UICC downstaging, ypN and ypT status), DFS, and overall
Time (months)
FIG. 3 Cox model for cancer-speciﬁc overall survival based on TS
score in pretherapeutic biopsies (p = 0.0151). The cutoff in the
Kaplan–Meier curves represents the median TS score and serves the
purpose of visualization
2448 L.-C. Conradi et al.TABLE 2 Multivariate analyses of TS expression in pretreatment biopsies and in surgical specimens in correlation with disease-free survival
and overall cancer-speciﬁc survival
Patient
characteristics
TS expression Relation Disease-free survival Cancer-speciﬁc survival
Biopsy score TS Univariate
analysis
Multivariate
analysis
Univariate
analysis
Multivariate
analysis
High[4
(N = 110)
Low B 4
(N = 55)
pp HR (95%
CI)
pp HR (95%
CI)
p
All patients - TS expression in pretreatment biopsy
Gender 0.39 0.05 2.5 (1.1–5.8) 0.03* 0.4 1.5 (0.5–4.2) 0.44
Male (%) 79 33
Female (%) 22 31
Age (yr) 0.79 0.07 1 (0.9–1) 0.08 0.24 1 (0.9–1) 0.43
B63 25 55
[63 30 55
uN 0.44 0.55 1.2 (0.6–2.4) 0.68 0.15 2.3 (0.7–8.3) 0.19
- 18 24
? 37 86
uT 0.27 0.89 0.9 (0.4–2.3) 0.83 0.68 2.1 (0.5–8.8) 0.3
1–2 4 6
3–4 51 104
TRG 1 0.34 0.35
0, 1, 2, 3a, 29 52 - - - - - - -
3b, 4 18 39 - - - - - - -
Neoadjuvant therapy
No 8 19
5-FU 25 54 0.78 0.43 1.1 (0.5–2.6) 0.81 0.24 0.9 (0.3–3) 0.9
5-FU ? Ox 22 37 0.77 0.45 1.3 (0.5–3.3) 0.54 0.36 1.2 (0.3–4.6) 0.75
TS biopsy 0.14 0.9 (0.8–1) 0.15 0.015* 0.7 (0.6–0.9) 0.01*
Patient characteristics TS expression Relation Disease-free survival Cancer-speciﬁc survival
Biopsy score TS Univariate
analysis
Multivariate
analysis
Univariate
analysis
Multivariate
analysis
High C 7
(N = 31)
Low\7
(N = 42)
pp HR (95% CI) pp HR (95% CI) p
(y)pN ? patients - TS expression in resection specimens
(y)pT 0.53 0.37 1.2 (0.7–2) 0.58 0.04* 2.3 (0.9–5.7) 0.08
1–2 7 8
3–4 24 34
Neoadjuvant therapy
No 7 13
5-FU 16 19 0.33 0.17 2.1 (0.8–5.6) 0.12 0.04* 4 (1.1–15.3) 0.04*
5-FU ? Ox 8 10 0.21 0.39 1.5 (0.5–4.8) 0.47 0.21 2.7 (0.5–14.4) 0.25
TS biopsy 0.18
Low B 45 2 4
High[41 1 1 7
TS tumor 0.04* 0.9 (0.8–1) 0.03* 0.35 0.9 (0.8–1.1) 0.55
* Signiﬁcant results
Thymidylate Synthase in Rectal Cancer 2449survival did not reveal any association in the analyzed
patient cohort that could currently be used for a speciﬁc
risk assessment.
DISCUSSION
Our analysis is the largest study so far to characterize
TS expression from pretherapeutic biopsies and the cor-
responding surgical specimens from patients with rectal
cancer treated in multimodal concepts.
22 Although pre-
vious analyses of smaller patient cohorts reported high
TS expression as a negative prognostic biomarker, recent
data, in accordance with our present ﬁndings, have
shown a beneﬁt for patients with high intratumoral TS
expression.
23,25,43–46
Within previous studies, Jakob et al.
43 evaluated TS
expression levels in 40 patients and found a correlation
between low TS expression and TRG. In patients with RCT-
induced pCR (TRG-4), we observed an excellent clinical
course without any cancer recurrence during the follow-up
period. Moreover, tumor regression grades between 1 and 3
didnotpredictlong-term survival.In further analyses,based
on a very small patient cohort, Jakob et al. postulated that
high TS levels indicated unfavorable prognosis in patients
with cancer recurrence (n = 9) without RCT-induced UICC
downstaging. This hypothesis was supported by several
other studies as reviewed by Kuremsky et al.
22; however,
they primarily investigated the correlation with local
response parameters, out of the context of DFS and overall
survival. Other reasons for opposite conclusions of previous
studies might be rooted in a lack of differentiation between
colonandrectalcancer,limitedanalyseswithresultsderived
from small subgroups, and ﬁnally different methodological
approaches.
We evaluated TS protein level by IHC, because it can be
easily implemented into clinical routine. Another approach
to investigate the impact of TS was the pharmacogenetic
analysis of gene polymorphisms.
47 A comparative analysis
of quantitative TS protein expression detected by IHC and
genotype also conﬁrmed the coherence of the TS poly-
morphism with intratumoral expression activity. Aside
from the analyses of single nucleotide polymorphisms, a
28-bp repeat within the TS gene seems to be of inter-
est.
42,48,49 A correlation between the number of 28-bp
repeats and gene and protein expression efﬁcacy has been
repeatedly found and conﬁrmed by our investigations.
50,51
Low TS expression from pretherapeutic biopsies showed
prognostic value with respect to impaired CSS. Based on
these ﬁndings, one could conjecture a beneﬁt from the
intensiﬁcation of neoadjuvant RCT protocols, especially
for patients who do not sufﬁciently respond to preoperative
RCT with 5-FU monotherapy. Indeed, a better outcome for
patients with low TS expression was observed under the
intensiﬁed treatment with 5-FU and oxaliplatin, although
these data originated from a subgroup analysis. A pro-
spective validation of this observation in a large patient
cohort would be crucial for implementing the prethera-
peutic TS expression level assessment into clinical
practice. Within a prospectively randomized clinical trial,
stratiﬁcation of patients for the neoadjuvant RCT regimen
as well as for the adjuvant treatment according to TS
expression and further markers for the patients’ individual
risk would be the next step toward individualized therapy.
CONCLUSIONS
This study demonstrates the prognostic value of TS in
locally advanced rectal cancer treated with multimodal
A B C
Time (months) Time (months) Time (months)
FIG. 4 Cox model for disease-free survival based on TS score in
resection specimens. The cutoff in the Kaplan–Meier curves repre-
sents the median TS score and serves the purpose of visualisation.
a Trend of better disease-free survival for patients with high TS
expression in the complete patient cohort (p = 0.213). b Patients
with histopathologically proven lymph node metastases and low TS
expression show an increased disease-free survival (p = 0.0406).
c Patients with nodal negative show the most favorable disease-free
survival during follow-up independent of TS expression (p =
0.168)
2450 L.-C. Conradi et al.5-FU-based RCT. The analyses show an unfavorable
prognosis in patients with low intratumoral TS expression.
Standardized IHC staining could easily integrate TS anal-
ysis into routine staging procedures and could be used for
stratiﬁcation of adjuvant therapy. Particularly, patients with
persistent positive lymph node status and low TS expres-
sion in the resected specimen are at a higher risk for cancer
recurrence. These patients might beneﬁt from an intensiﬁed
treatment regime and potential higher rates of therapy-
associated toxicity might be justiﬁed. Prospective valida-
tion in future clinical trials is crucial for legitimating the
treatment stratiﬁcation based on the TS expression level.
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